Introduction
Direct injection of plasmid DNA into skeletal muscle is one of the most straightforward ways to carry out gene transfer in vivo for the purposes of gene therapy. However, compared with the use of viral vectors it is relatively inefficient, with the earliest reports of direct plasmid gene transfer into skeletal muscle showing transfection efficiencies of approximately 1% of muscle fibres. 1, 2 Many factors, such as the solute used, injection technique, animal age and plasmid construct design, have since been investigated and have resulted in improvements in efficiency. [3] [4] [5] [6] [7] None of these, however, has resulted in the dramatic improvement seen with the advent of electrotransfer. [8] [9] [10] When applying electrotransfer, a balance needs to be reached between the voltage applied, which determines the level of transgene expression, and the ensuing damage to the muscle. 10 It has been proposed that electrotransfer consists of two components: electroporation (formation of inverted hydrophilic pores in the cell membrane) followed by electrophoresis of the DNA into the cell. 11, 12 The failure of muscle fibres to recover from the permeabilisation of the sarcolemma or the possible thermal effects of the current flow between the applied Correspondence: DJ electrodes leads to muscle fibre degeneration. Healthy muscle recovers rapidly from damage by activation of satellite cells and myoblast fusion to regenerate muscle fibres. Hence, where plasmid gene transfer into skeletal muscle is carried out for induction of an immune response (genetic vaccination), or for systemic delivery (eg apoE, factor IX, erythropoietin), the damage caused when using current electrotransfer protocols may not be significantly detrimental. 11, [13] [14] [15] However, for treatment of muscle disease by gene replacement, for example, in the case of muscular dystrophies, it is essential to ensure the survival of muscle fibres while maximising the number of transfected fibres.
The efficiency of plasmid transfer into muscle is highest in small, young rodents, for example, rapidly growing male mice. 3 Danko and colleagues 16 reported very high expression in mice at 14 days old. In larger species, there is a dramatic reduction in the efficiency possibly due to the level of connective tissue present in the muscle. 17 Induction of regeneration with reagents such as barium chloride or notexin may enhance the access of DNA to the young myotubes but expression may also be increased due to increased transcription levels. [18] [19] [20] [21] Uptake can also be enhanced by the use of pressure systems, which has been successful in rats. 22 The half-life of plasmid in serum has been reported as being between 5 and 10 min after intravascular administration and therefore uptake needs to be a rapid event for maximal efficiency. 23, 24 Together, these data suggest that one limitation to plasmid gene transfer is the access of the plasmid DNA to the muscle fibre surface.
Skeletal muscle fibres are surrounded by a plasma membrane, the sarcolemma. An extra-cellular matrix (ECM) or endomysium containing hyaluronan and collagen surrounds each fibre. Groups of fibres are divided into fascicles by a further ECM barrier, the perimysium, and finally the epimysium surrounds the entire muscle. Many muscles are pennate in structure with muscle fibres attached to connective tissue in the centre of the muscle. Together, these structures form barriers to the local delivery of plasmid DNA. Injection of a sucrose solution, before injection of plasmid, has been shown to force the generation of spaces between muscle fibres and hence improves the distribution of plasmid throughout the muscle. 4 Specific enzymes such as hyaluronidase and collagenase, which break down components of the extracellular matrix, are used for dissociation of muscle during preparation of primary myoblast cultures. In 1984, hyaluronidase was used to improve delivery of calcium chloride plasmid DNA precipitates to the liver 25 and has since been used to improve adeno-associated virus vector delivery to skeletal muscle. 26 The article describes pretreatment of skeletal muscle with hyaluronidase followed by electrotransfer of plasmid DNA to improve the transfection efficiency of plasmid gene transfer within the injected muscle. Experiments were analysed both in terms of the overall levels of gene expression obtained and of the number of transfected fibres. The distribution of the transfected fibres and the damage occurring in the muscle was taken into consideration during optimisation of the electrotransfer protocol. The equipment chosen was commercially available (BTX ECM 830 electroporator with Tweezertrodes) allowing application of the same parameters by other groups working on plasmid gene transfer into skeletal muscle.
Results
In vivo electrotransfer of plasmid DNA into skeletal muscle In our initial experiments, the electrotransfer parameters described by Mir et al 9 were selected. Plasmid DNA (pCMV␤) was prepared at a dilution of 1 mg/ml in normal saline (0.85%) and 25 l of plasmid solution was injected into each tibialis anterior (TA) muscle of 6-to 8-week-old C57Bl10xCBA/Ca (F1) male mice, followed immediately by application of electric pulses. A voltage of 200 V/cm was applied in 10 20 ms pulses at 1 Hz. Application of the voltage resulted in marked muscle twitching in the treated muscle and many other muscle groups in the animal. After recovery from anaesthesia the animals showed no obvious signs of loss of muscle performance or discomfort. At the time of sampling, 5 days after treatment, white lesions were visible on the surface of many injected muscles; these lesions consisted of scarring both in the muscle fascia and within the muscle itself. Quantitation of ␤-galactosidase-positive fibres showed that 16.9% (±2.8) of muscle fibres were transfected compared with 1.4% (±0.6) transfection when no electric field was applied (Figure 1a-d) . Microscopic examination of the muscles revealed large areas of degenerated muscle, particularly concentrated at the areas of the muscle closest to the site of application of the electrodes (Figure 1a-c) . Only a few isolated transfected fibres were seen in these areas of damage and the Gene Therapy majority of transfected fibres were distributed in the central portion of the muscle. In many cases, expression was detected only on one side of the central connective tissue barrier in the TA muscle. A small number of treated muscles consisted almost entirely of regenerated muscle fibres, indicating widespread damage and resulting in much lower transgene expression levels.
Effects of hyaluronidase pre-treatment
Using the same electrotransfer parameters, plasmid was injected into muscles that had been treated 2 h previously with bovine hyaluronidase at a concentration of 0.4 U/l in 25 l of normal saline. In this experiment, the average level of expression was lower than the preceding experiment but hyaluronidase pretreatment produced substantially higher levels of expression, with an average of 17.9 (±8.3)% of fibres being transfected, compared with electrotransfer with pre-injection of saline which resulted in transfection of 1.5 (±1.2)% of the muscle. It also resulted in transfected fibres being distributed across a larger proportion of the tibialis anterior ( Figure 1e ). The area of damage was more limited but was still severe in the areas closest to the electrodes. Muscles pretreated with hyaluronidase, but not subject to electrotransfer, showed no additional damage compared with those treated with saline. However, in the absence of electrotransfer, expression was low (hyaluronidase 0.7 (±0.4)% and saline 0.6 (±0.2)%), and no improvement was seen with the hyaluronidase treatment alone.
Optimisation of electrotransfer voltage
In order to assess the effect of field strength on damage and expression, groups of four male 6-to 8-week-old F1 mice were injected with plasmid DNA followed by electrotransfer using the following voltages: 200, 175, 150, 125, 100 and 0 V/cm. There was a proportional increase in the number of transfected fibres with increasing field strength above 100 V/cm. (Figure 2a) . Total ␤-galactosidase expression was not significantly different between groups subjected to 175, 150 and 125 V/cm, and all showed a decrease compared with the group at 200 V/cm (Figure 2b) . However, the number of transfected fibres was not significantly different at 175 V/cm compared with 200 V/cm ( Figure 2a ) and distribution of the transfected fibres and the level of muscle regeneration, as indicated by NCAM immunostaining, showed that there was a substantial reduction in the area of muscle damage (Figures 2c and 3) . The decreased total expression but similar transfected fibre number at 175 V/cm compared with 200 V/cm suggests a decrease in the number of copies of plasmid taken up into each fibre at 175 V/cm.
Hyaluronidase pre-treatment and optimised electrotransfer
The above results suggested that both the field strength and the access of the plasmid to the muscle fibres were important and that 200 V/cm was causing an unacceptable level of muscle damage. Therefore, hyaluronidase pre-treatment was combined with a field strength of 175 V/cm. In addition, some groups were subjected to electrotransfer immediately following the injection of plasmid DNA (as in the above experiments) whilst other groups were subjected to electrotransfer 5 min after injection of plasmid DNA. The pre-treatment of the injected muscle with hyaluronidase resulted in a significant increase both in total expression levels and in the percentage of transfected fibres compared with the control muscles which received an injection of saline in place of the enzyme (Figures 4 and 5) . Further hyaluronidase pretreatment experiments (not described) using these parameters have resulted in similar transfection levels (49.4% ± 6.3). There was no significant difference in expression or damage whether the muscles were subjected to electrotransfer immediately after plasmid injection or with a 5 min delay between the two treatments. The injected muscles showed widespread distribution of ␤-galactosidase-positive fibres across the entire muscle in some cases. In others, however, the connective tissue barrier was clearly limiting the expression to one side of the muscle (Figure 5c ). Hyaluronidase pretreatment did not result in an increase in muscle damage compared with saline pretreatment. Dropping the voltage to 150 V/cm following hyaluronidase pretreatment was associated with a decrease in the number of transfected fibres compared to 175 V/cm (data not shown). 
Discussion
Gene transfer into skeletal muscle has been proposed for replacement gene transfer, as a platform for systemic production of therapeutic proteins and for genetic vaccination. Skeletal muscle can be genetically modified using a variety of vectors including recombinant adenovirus, 27 ,28 recombinant retrovirus, 29, 30 recombinant adenoassociated virus 31, 32 and naked plasmid DNA. 1, 18 The last of these has the advantage in that new constructs can be made readily and repeated administration is possible in immunocompetent animals, whereas vector-specific neutralising antibodies (and in some cases cytotoxic responses) seriously limit the possibility of repeated administrations of the viral vectors. 33, 34 Additionally, plasmid DNA can be readily produced and batch validated on a pharmaceutical scale 35 and has a good safety record in genetic vaccination clinical trials. The major concern with this nonviral vector system is the relatively low efficiency of transfection following injection into muscle. This concern has recently been addressed by the development of in vivo electrotransfer techniques that have routinely achieved a 10-to 100-fold increase in expression. [8] [9] [10] 15 The LacZ reporter gene was used in present studies, as its expression is easily quantifiable by histochemistry and ELISA thus allowing an assessment of both the number of positive fibres and the overall levels of expression. Samples were taken at 5 days after injection, as this represents the peak of ␤-galactosidase expression in these animals following direct injection alone. 36 Longer-term studies in immunocompetent ani-
Gene Therapy

Figure 4 Total level of expression of ␤-galactosidase in muscle homogenates from tibialis anterior muscles subjected to treatment with either saline or hyaluronidase 2 h before injection of plasmid DNA. The electroporation voltage of 175 V/cm was applied either immediately following plasmid injection (solid) or after an interval of 5 min (striped). (b) The percentage of muscle fibres transfected (area of blue fibres per area of muscle) from the contralateral TA muscles, subjected to the same conditions as in (a) (n = 4 in each group). Error bars shown are standard error values.
mals are confounded by immune responses to the reporter gene product. The anterior tibial muscle was chosen for these studies as it is easy to inject percutaneously, locomotion is not significantly affected by damage to the muscle and the electrodes can be conveniently placed either side of the lower hindlimb. In the experiments, commercially available electrodes were used so that other laboratories can use the same conditions. The results demonstrate that hyaluronidase pretreatment of skeletal muscle substantially improves gene expression following direct injection of plasmid with electrotransfer. Indeed, the improved gene transfer associated with the hyaluronidase treatment allows a reduction in the voltage that needs to be applied to the muscle for high efficiency gene transfer. This reduction in voltage leads in turn to a substantial reduction in damage to the muscle. High efficiency gene transfer, without concomitant muscle damage, should widen the potential application of this technology. Previous reports of high efficiency electrotransfer have also noted the association of muscle damage with efficient gene transfer. 10 Other studies, however, have failed to comment on the muscle histology 9, 15 although in some cases the figures showed evidence of muscle damage. 8 Hyaluronidase has previously been used to improve the efficiency of virus-based in vivo gene transfer methods. 26, 37 It has also been used to enhance nonviral gene transfer in vitro. 38 In the present study, we could not identify any pathology associated with the hyaluronidase pretreatment suggesting that the dose used in these experiments provided some permeability of the connective tissue barriers without total disruption. This is not altogether surprising as hyaluronidase is used clinically to minimise tissue damage following extravasation of parenteral nutrition solutions. 39 It is also known to reduce ischaemic injury to myocardium 40 and has been shown to reduce oedema caused by the rejection of transplanted organs. 41 There remained some variation between animals both in damage and gene expression. The field strength was not precisely adjusted for each animal and this could have led to some of the variation. In addition, the precise needle placement clearly influences the extent of transfection. Where the needle has only penetrated the superficial portion of the muscle, transfection is confined to the outer part of the muscle by the presence of a central tendon (Figure 4c) . Finally, as previously reported, 42 the injection process can cause variable damage probably related to interruption of blood supply to areas of the muscle.
Plasmid DNA has stimulatory effects on the mammalian immune system that depend on the presence of unmethylated CpG dinucleotides in the prokaryotic DNA. In contrast, mammalian DNA has a low frequency of CpG dinucleotides, most of which are methylated. Injection of plasmid DNA into skeletal muscle stimulates a strong inflammatory response that is not dependent on the presence of a transgene. 42 We noted that the combination of electrotransfer and hyaluronidase treatment did not lead to any increase in the number or size of inflammatory lesions, normally associated with injection of CMV␤ plasmid. This is somewhat surprising, as the combined treatments result in increased distribution of the plasmid, and hence a wider distribution of immunostimulatory unmethylated CpG motifs. This suggests that the increased efficiency of plasmid uptake, associated with electrotransfer, may be due to plasmid DNA passing into cells via a different route. Recent work has shown that the effects of the unmethylated CpG dinucleotides are mediated via a Toll-like receptor, TLR9. 43 Although there is some debate about the requirement for internalisation to obtain CpG stimulation of immune cells, [44] [45] [46] [47] the immunostimulatory effect can be blocked by chloroquine and related compounds suggesting a role for endocytosis in the CpG-driven activation of the immune system. 45, 48 The electrotransfer of plasmid probably avoids the endosomal pathway by directly introducing the plasmid into the cytoplasm of the cell and thus reducing the pool of unmethylated CpG dinucleotides available for stimulation of the TLR9. This is an unexpected but useful sideeffect of the electrotransfer process and might be predicted to tend towards development of a Th2 type of immune response to any immunogenic transgene rather than the Th1 response that is more commonly encountered using DNA vaccination. 49 Electrotransfer has been shown to improve the efficiency of plasmid gene transfer and expression in other species apart from the mouse. 9, 50 As the connective tissue barrier has been identified as a major limitation to plasmid gene transfer in larger animals, 17 use of hyaluronidase pretreatment can be predicted to be increasingly beneficial in larger species. Hence, the application of this combination of techniques makes plasmid DNA a real clinical alternative to viral vectors.
Materials and methods
Preparation of plasmid DNA
The plasmid CMV␤, containing the ␤-galactosidase gene under the control of the cytomegalovirus (CMV) immediateearly promoter (Clontech, Palo Alto, CA, USA), was grown in XL1Blue (Stratagene, La Jolla, CA, USA) and purified using ENDofree plasmid kits from Qiagen (Crawley, UK) following the supplier's protocol. Identity was confirmed by agarose gel electrophoresis of both uncut and restriction digested plasmid. Contamination with RNA was not observed and the majority of the plasmid was present as covalently closed circles. The plasmid preparation contained Ͻ0.001 EU/g endotoxin (lipopolysaccharide) contamination as assessed using Pyrogent 500 turbimetric assay (BioWhittaker, Wokingham, UK).
Intramuscular injection of plasmid DNA
In vivo experiments were carried out on 6-to 8-week-old C57Bl10xCBA/Ca (F1) male mice. Animals were housed in a minimal disease facility with food and water ad libitum. Plasmid DNA (1 g/l) in normal saline was injected percutaneously. All injections (25 l) were carried out using a 27-gauge needle in a proximal to distal direction inside the anterior tibial muscle, under fentanyl/fluanisone and midazolam general anaesthesia (respectively, Hypnorm, Janssen Animal Health, High Wycombe, UK and Hypnovel, Roche, Welwyn Garden City, UK) as previously described. 7 Following the intramuscular injection of plasmid DNA an electrical field was applied to the muscle. The injected leg was held steady and the 7-mm circular electrodes (BTX, Tweezertrodes; Kramel Biotech, Cramlington, UK) were applied to the medial and lateral sides of the lower hindlimb with reasonable pressure to maintain contact with the skin surface. Electrode jelly was used on the electrode plates to ensure good electrical contact. A voltage ranging between 100 and 200 V per centimetre was applied in 10 20 ms square wave pulses at 1 Hz using a BTX ECM 830 electroporator. Samples were then collected 5 days after the injection of plasmid DNA.
In some experiments, the TA muscles were pretreated 2 h before plasmid injection. The muscles were injected with 0.4 U/l of bovine hyaluronidase (H-4272; Sigma, Poole, UK) in 25 l of normal saline. Control groups were left untreated or the muscles were given a 2 h pretreatment with 25 l of normal saline.
Collection of samples
Mice were killed by cervical dislocation. Both anterior tibial muscles were excised post mortem and the right muscle was snap-frozen in liquid nitrogen. The left muscle was mounted on a cork block, embedded in Cryo-M-Bed (Bright, Huntingdon, U.K.) and snap-frozen in liquid nitrogen-cooled isopentane. The frozen muscles were stored at −70°C. For analysis of transfected fibre number and damage, 10 m cryostat sections were cut at a minimum of 10 evenly spaced levels throughout each muscle and lifted on to APES-coated slides. 51 Slides were stored at −70°C after air-drying.
Histology
Standard haematoxylin and eosin staining was carried out in order to assess cell morphology and inflammatory infiltrate. Further analysis was performed using immunostaining with antibody to the cell adhesion molecule NCAM which is expressed in myoblasts and young myotubes. Cryosections were fixed in ice cold acetone for 10 min, blocked with avidin/biotin blocking reagent and then with 5% dried milk in TBST. Antibody to NCAM (Boehringer, Lewes, UK) was used at 1:100 and bound antibody detected with biotinylated secondary antibody followed by HRP-conjugated streptavidin-biotin complex and DAB. Slides were counter stained with haematoxylin or Giemsa to show the nuclei before dehydration through graded alcohols, clearing in xylene and mounting in DPX (BDH, Poole, UK).
X-gal staining for ␤-galactosidase was carried out as follows: cryostat sections were fixed in 2% formaldehyde in 100 mm phosphate-buffered saline (10× PBS) for 5 min and then washed in PBS. Slides were incubated overnight at 37°C in X-gal staining solution (1 mm X-gal, 5 mm potGene Therapy assium ferrocyanide, 5 mm potassium ferricyanide, 2 mm MgCl 2 in PBS). Sections were counterstained in 1% alcoholic eosin, dehydrated through graded alcohols, cleared in xylene and mounted in DPX.
A Leica DMLB research microscope (Leica, Wetzler, Germany) with a colour JVC Ky-F55B 3-CCD camera was used to import images to a computer. Images were captured using SnapperTool version 2.04 software from DataCell, Maidenhead, UK. Further image orientation was carried out using Adobe Photoshop version 5.0.2 (Polaroid, Adobe Systems, Edinburgh, UK).
When transfection efficiencies were too high to allow individual fibre counts, percentage transfection was calculated by measuring the cross-sectional area of blue fibres and expressing this as a percentage of the total cross-sectional area of the muscle. Muscle damage was quantified in a similar manner by calculating the area of damaged fibres and expressing them as a percentage of the cross-sectional area of the muscle. Calculations were carried out using SigmaScan Pro version 5.0.0 image analysis software from SPSS (Birmingham, UK).
␤-Galactosidase ELISA For analysis of total ␤-galactosidase expression, a tibialis anterior muscle was homogenised in a microfuge tube with a micropestle in 200 l of lysis buffer (␤-galactosidase ELISA kit from Boehringer, Lewes, UK) together with a cocktail of protease inhibitors (50 g/ml antipain, 10 g/ml aprotinin, and 0.5 g/ml leupeptin). The volume was increased to a total of 400 l and the tissue subjected to three rounds of freeze-thaw cycles. After mixing thoroughly, the solution was spun at 13 000 r.p.m. for 10 min to pellet all insoluble material. Supernatants were stored at −70°C until assayed. For each assay equal volumes of supernatant was diluted to 200 l and assayed using the ␤-galactosidase ELISA kit as per the manufacturer's instructions.
Statistical analysis
Statistical analysis was carried out by one-way ANOVA followed by multiple-paired comparison. Groups were considered significantly different when P Ͻ 0.05. Statistical tests were conducted using Sigma-Stat from SPSS. Error bars shown on Figures 2 and 5 and values given in the text are standard error values.
